HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment

• Published in: Scientific reports 2020-09, Vol.10 (1), p.15750-15750, Article 15750
• Main Authors: Wuerfel, Franziska M., Huebner, Hanna, Häberle, Lothar, Gass, Paul, Hein, Alexander, Jud, Sebastian M., Hack, Carolin C., Wunderle, Marius, Schulz-Wendtland, Rüdiger, Erber, Ramona, Hartmann, Arndt, Ekici, Arif B., Beckmann, Matthias W., Fasching, Peter A., Ruebner, Matthias
• Format: Article
• Language: English
• Subjects: 692/4028/67/1347; 692/53/2423; Adult; Aged; Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Female; Gene Expression Regulation, Neoplastic; Histocompatibility Antigens Class I - metabolism; HLA-G Antigens - metabolism; Humanities and Social Sciences; Humans; Middle Aged; multidisciplinary; Neoadjuvant Therapy - methods; Prognosis; Prospective Studies; Protein Isoforms - metabolism; Receptor, ErbB-2 - metabolism; Science; Science (multidisciplinary); Treatment Outcome
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-020-72837-3

The immunosuppressive human leukocyte antigens HLA-G and HLA-F are expressed on trophoblast and malignant cells. Four membrane-bound and three soluble HLA-G protein isoforms have been described, which have different immunosuppressive potentials. HLA-F has three transcript variants, resulting in three different protein isoforms. The aim of this study was to evaluate the prognostic and predictive value of HLA-G and HLA-F protein isoform expression patterns in patients with breast cancer. Core biopsies were taken at diagnosis in patients with HER2+ (n = 28), luminal B-like (n = 49) and triple-negative (n = 38) breast cancers who received neoadjuvant chemotherapy. Expression levels of HLA-F and -G were correlated with the pathological complete response (pCR). Protein expression was determined by Western blot analysis, using two antibodies for each HLA, specific for different isoforms. The protein expression of HLA isoforms did not significantly differ between breast cancer subtypes. However, some initial indications were found for an association between the soluble HLA-G6 protein isoform and pCR in HER2+ breast cancer. The study provides preliminary evidence for the evaluation of HLA-G isoform expression, in particular HLA-G6, as a possible new marker for pCR in HER2+ breast cancer.